RT Oncology provides oral oncology drugs to community oncologists to improve efficiencies and patient care.
The Company raised the first tranche of their Series A financing, which includes additional performance based tranches. To determine the fair value of the common stock, we needed to establish the likelihood of future financings and their dilutive effect. We did this by modeling the future value of the Company using Monte Carlo techniques.